Innovation of multi-Drug delivery platform based on the ssPalm: Immune-engineering and cancer therapy

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H01806
• Research Category: Grant-in-Aid for Scientific Research (A)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Biomedical engineering/Biomaterial science and engineering
• Research Institution: Chiba University (2016-2017); Hokkaido University (2015)
• Principal Investigator: Hidetaka Akita 千葉大学, 大学院薬学研究院, 教授 (80344472)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 癌免疫 / ナノ粒子 / 環境応答性材料 / ワクチン / DNA

Outline of Final Research Achievements

For the success of the cancer immune therapy, activation of antigen-specific cytotoxic T cell (CTL) is quite important. DNA vaccine is principally useful technology to induce this CTL activity. Meanwhile, the intra-tumor region is considered to be an immune-suppressive environment. Thus, for the effective function of the cancer vaccine, the normalization/ neutralization of the immune-suppressive machinery is essential in parallel.
Currently, we have developed a lipid nanoparticle composed of intracellular environment-responsive material (ss-cleavable and pH-activated lipid-like material: ssPalm) as a technology to overcome the biomembranes barrier, and spontaneous collapse. In this project, we developed a delivery system of Genes, and small compounds using ssPalm as a fundamental platform, and applied them for the immune-engineering for cancer therapy.

Free Research Field

薬剤学